Health Tech Forward Event 2024

Manufacturer of medical equipment company intended to provide chronic pain relief devices. The company use monitoring and cutting-edge AI system will revolutionize the domain of chronic pain for both patients and healthcare professionals, enabling patients to give an advance and efficient pain relief medical equipment.

Convergence Partners is a pan-African tech focused private equity player, delivering enhanced investment returns while underpinning Continental development. We have a proven track record of developing new investment opportunities as well as active adding value to investments across the lifecycle of tech assets. As impact investors, Convergence Partners brings its skills, experience and capital to accelerate ICT infrastructure development in Africa, focusing on initiatives that increase availability of communications, broadband services and new technology offerings to the people of Africa

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Developer of a monitoring device designed to continuously track hormone levels in patients undergoing fertility treatments. The company's device monitors hormone levels directly from subcutaneous tissue to make informed treatment decisions, enabling healthcare providers to implement preventive measures before complications arise.

Developer of a modular analysis system designed to provide easy access to the analysis of all kinds of biomedical data. The company's platform allows pharma and biotech companies to analyze biomedical data without access to trained personnel, enabling clients to get access to quality and biologically relevant analyses.

Growth debt for scale-up businesses. Take your next step to growth with Bootstrap Europe. We provide progressive, ambitious entrepreneurs and shareholders with non-dilutive funding to help them succeed.

Developer of a cold plasma technology designed to heal chronic wounds. The company's technology focuses on diabetic foot wounds, kills bacteria, stimulates cell proliferation, and improves microcirculation, enabling doctors to decrease the risk of amputation and increase the quality of life for patients.

We are a venture capital firm that invests in the best impact startups.